The increasing use of PD‐(L)1 inhibitor particularly in first‐line treatment in patients with advanced lung cancer potentially leads to a situation, in which definitive or palliative doses of TRT are conducted in close sequential succession for consolidation therapy or salvage therapy. The gene discussed is CD274; the disease is lung carcinoma.